New Nitro PDF Pro Release Enables Accessible, Inclusive and Compliant PDFs for All
Nitro Software, a global leader in SaaS PDF, eSign and business document solutions, launched new document accessibility features as part of the latest release of Nitro PDF Pro, its flagship product. Driven by its mission to provide easy-to-use, inclusive and compliant technology for all people and organizations, Nitro teamed up with digital accessibility solution provider Level Access.
“Everyone deserves access to digital information, and that includes the more than 1.3 billion people globally who identify as having a disability,” says Jonathon Avila, Chief Accessibility Officer at Level Access. “It has been deeply rewarding to support Nitro in providing innovative solutions that contribute to a more accessible digital world.”
Why do organizations need tools to create accessible PDF documents?
Document accessibility features are used by people with a range of needs, including those who are blind or have low vision. For organizations, particularly in higher education and government, accessibility features have a far-reaching and long-term impact on goals including:
Inclusivity: All people, including people with disabilities, should be equipped with technology that enables their success. With document accessibility tools, people with disabilities can participate and contribute equitably in education, the professional world and their communities.
Recruiting: Meeting the needs of all employees is a key differentiator for organizations during the recruiting and hiring process. Companies that prioritize the accessibility of documents and other digital information are at an advantage when competing for diverse talent.
Compliance: Many organizations are legally required to procure technology that meets accessibility compliance standards.
How is Nitro making documents more accessible and inclusive?
The latest Nitro PDF Pro release provides an intuitive solution for a vast and growing market seeking reliable tools that ensure document accessibility, inclusivity and compliance.
“Whether permanent, temporary or situational, we are all likely to experience disabilities in our lives. Nitro is a diverse and inclusive company, and we are proud that our latest release of Nitro PDF Pro provides capabilities for equal access to PDFs in the workplace, classroom, at home and everywhere in between,” says Sam Thorpe, Nitro’s Chief Product Officer. “The partnership with Level Access has been exceptionally valuable to ensure the software we design is aligned to the accessibility needs of people and organizations around the world.”
New features and enhancements in the latest release of Nitro PDF Pro include:
-
Accessibility features making it fast and easy to create accessible, compliant PDFs, such as:
- Auto-tagging documents, tables and lists in a few simple steps
- Assigning accessibility tags, roles and reading order in tagged PDFs
- Managing artifacts
- Specifying human languages of tagged PDFs
- Embedding fonts
- Supplying alternate text
- Marking PDF/UA compliance
- Fresh new UI with a modern, easy-to-navigate experience
- Expanded list of language installers
To learn more about creating accessible and compliant PDFs, join Nitro and Level Access for an educational webinar on June 8, 2023.
Explore more of what’s new in the latest release of Nitro PDF Pro.
About Nitro Software
Nitro is a global SaaS leader in PDF document management and eSigning. Nitro’s Productivity Platform includes powerful PDF tools, digital workflow automation, highly secure eSigning and identity capabilities. Its analytics solution measures and quantifies ROI, usage and sustainability impact. With a best-in-class customer success team, Nitro supports more than 67% of the Fortune 500, 3 million licensed users and 13,000+ business customers across 157 countries. For more information: visit https://gonitro.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005546/en/
Contact information
Media Contacts
Nitro Software media@gonitro.com
Bospar for Nitro Software prfornitro@bospar.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom